en / es /

OWL Metabolomics Announces Scientific and Commercial Participation at The Liver Meeting® 2023

Scroll down
Published on 11/10/2023
By OWL Metabolomics
Share: Linkedin Facebook Twitter

(Bilbao, Spain, October 11, 2023) OWL Metabolomics will repeat its involvement at the upcoming The Liver Meeting® 2023 hosted by the American Association for the Study of Liver Diseases on November 10-14, 2023 in Boston, MA.

This year, OWL will be involved as a Scientific Contributor presenting recent metabolomics-based liver research findings in poster sessions, as described below:

Saturday, November 11; 1:00 PM – 2:00 PM. Hall A (plaza level)

Saturday, November 11; 1:00 PM – 2:00 PM. Hall A (plaza level)

OWL’s commercial participation will include a collaboration in the industry booth of CIMA Sciences in the Hall A of the Hynes Convention Center (Booth #B1222), together with LUXOR Scientific. OWL staff welcome your visit to our booth and suggest that a time be reserved for a brief discussion during the standard booth hours: Saturday 11 (6:00-7:30 p.m.), Sunday 12 (9:30 a.m.-4:30 a.m.) and Monday 13 (9:30 a.m.-4:30 a.m.).

Please contact the OWL Meeting Administrator, Miguel Campo, (mcampo@owlmetabolomics.com), to help identify a meeting time with our staff.

OWL’s long-standing focus on fatty liver disease progression, diagnosis

OWL Metabolomics collaborates with numerous pharma and biotech research organizations in the liver field throughout the world by constructing unique metabolomics-based analyses to determine specific changes in disease status and changes in disease severity within a variety of fatty liver patient types.
OWL has been involved in active MASH (Metabolic dysfunction-Associated SteatoHepatitis)-related metabolomic research for over 17 years, including metabolomics-based pre-clinical analysis in early-candidate drug studies, verification of treatment-arm parity at baseline, active human trial monitoring (i.e., surrogate marker of drug effect, monitoring of therapeutic impact / dose effects), and the development of tailored companion diagnostics to more accurately predict potential patient responders to a given drug treatment.
In addition to the detailed MASH research collaborations with pharma, OWL Metabolomics has produced and validated the OWLiver® panel, the only NON-invasive laboratory test based on metabolomics technology that determines liver activity through the evaluation of 28 metabolites, with a primary goal of reducing the need for more invasive or more expensive testing modalities, including the invasive liver biopsy. Today’s international ‘gold-standard’ for the definitive diagnosis of MASH remains a cumbersome and expensive invasive tissue biopsy procedure. The key benefit of such blood-based advanced testing is that it can be performed safely at frequent intervals allowing patient monitoring.

History of OWL Metabolomics

OWL Metabolomics, a Rubió Group company, is a global metabolomics service provider to the pharma industry with a main focus supporting clinical trials in liver diseases and other prevalent human diseases as well as research in indications where metabolomic plays a key role, including drug therapy monitoring and biomarker discovery.
OWL Metabolomics is also committed to the identification, validation and global commercialization of novel diagnostic assays for liver diseases. Since its inception in 2002, OWL Metabolomics has pioneered unique diagnostic research within the fatty liver space, a field of considerable focus in MASH drug development.

Our site uses cookies to collect information about your device and browsing activity. We use this data to improve the site, ensure security and deliver personalized content. You can manage your cookie preferences by clicking here.
Accept cookies Configure
Basic cookie information
This website uses cookies and/or similar technologies that store and retrieve information when you browse. In general, these technologies can serve very different purposes, such as, for example, recognizing you as a user, obtaining information about your browsing habits or personalizing the way in which the content is displayed. The specific uses we make of these technologies are described below. By default, all cookies are disabled, except for technical ones, which are necessary for the website to function. If you wish to obtain more information or exercise your data protection rights, you can consult our "Cookie Policy".
Accept cookies Configure
Technical and/or necessary cookies Always active
Technical cookies are those that facilitate user navigation and the use of the different options or services offered by the website, such as identifying the session, allowing access to certain areas, facilitating orders, purchases, filling out forms, registrations, security, facilitating functionalities. (videos, social networks...).
Analysis cookies
Analysis cookies are those used to carry out anonymous analysis of the behavior of web users and that allow user activity to be measured and navigation profiles to be created with the objective of improving websites.
Confirm preferences
Linkedin Twitter
By Rubió
Carrer Indústria 29, Polígon Industrial Comte de Sert 08755
Castellbisbal, Barcelona (España), +34 937 722 509labrubio@labrubio.com